...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Effects of Valsartan on Fibrinolysis in Hypertensive Patients With Metabolic Syndrome – The KACT-MetS Study –
【24h】

Effects of Valsartan on Fibrinolysis in Hypertensive Patients With Metabolic Syndrome – The KACT-MetS Study –

机译：缬沙坦对高血压代谢综合征患者纤维蛋白溶解的影响– KACT-MetS研究–

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The purpose of this study was to analyze the effect of valsartan on abnormal adipocyte metabolism and prothrombotic state in hypertensive patients with metabolic syndrome (MetS). Methods and Results: We conducted a multicenter, prospective, randomized, parallel-group controlled trial in 150 hypertensive patients with MetS. They were randomly assigned to receive either 80-160mg valsartan per day (valsartan group, n=79) or other conventional treatment without a renin-angiotensin system (RAS) inhibitor (non-RAS inhibitor group, n=71). After 1 year, there were no significant differences between the 2 groups in the changes in systolic and diastolic blood pressures (valsartan: 153±15/86±15 to 138±16/77±12mmHg; non-RAS inhibitor: 150±14/82±15 to 137±15/76±10mmHg). There was a significant difference in the change in the levels of plasminogen activator inhibitor-1 (PAI-1) between the 2 groups after 1 year (valsartan: 3.7±3.2ng/ml; non-RAS inhibitor: 5.8±3.3ng/ml, P=0.04). There was no significant difference between groups in the change in the concentration of adiponectin after 1 year (valsartan: 0.3±0.4μg/ml; non-RAS inhibitor: 0.9±0.4μg/ml, P=0.22). The animal study showed aortic PAI-1 protein expression was reduced in double knockout mice of angiotensin II type 1a receptor and apolipoprotein E (apoE) compared with the apoE knockout mice. Conclusions: Valsartan reduced plasma PAI-1 levels compared to non-RAS inhibitor in hypertensive patients with MetS, which suggests it may be useful for improving fibrinolytic function. ( Circ J 2012; 76: 843-851)
机译：背景：本研究的目的是分析缬沙坦对患有代谢综合征（MetS）的高血压患者脂肪细胞代谢异常和血栓前状态的影响。方法和结果：我们在150名高血压MetS患者中进行了一项多中心，前瞻性，随机，平行分组的对照试验。他们被随机分配每天接受80-160mg缬沙坦（缬沙坦组，n = 79）或其他不使用肾素-血管紧张素系统（RAS）抑制剂的常规治疗（非RAS抑制剂组，n = 71）。一年后，两组的收缩压和舒张压变化无明显差异（缬沙坦：153±15/86±15至138±16/77±12mmHg;非RAS抑制剂：150±14 / 82±15至137±15/76±10mmHg）。 1年后两组之间纤溶酶原激活物抑制剂1（PAI-1）水平的变化存在显着差异（缬沙坦：3.7±3.2ng / ml;非RAS抑制剂：5.8±3.3ng / ml ，P = 0.04）。一年后脂联素浓度的变化在两组之间没有显着差异（缬沙坦：0.3±0.4μg/ ml;非RAS抑制剂：0.9±0.4μg/ ml，P = 0.22）。这项动物研究显示，与apoE基因敲除小鼠相比，血管紧张素II 1a型受体和载脂蛋白E（apoE）双基因敲除小鼠的主动脉PAI-1蛋白表达降低。结论：与非RAS抑制剂相比，缬沙坦可降低高血压MetS患者的血浆PAI-1水平，这可能有助于改善纤溶功能。 （Circ J 2012; 76：843-851）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号